Although the mechanism by which PPARγ acts on the pathogenesis of IBD has not been clarified (Decara et al., 2020), natural and chemical PPARγ ligands have ameliorated the fibrotic process in preliminary clinical trials and experimental models of intestinal fibrosis (Vetuschi et al., 2018). Here, PPARG is linked to inflammatory bowel disease.